




A




B



C



D



## Supplementary Figure 5:

**A** Gating strategy for the analysis of integrin expression and vedolizumab (VDZ) binding.

**B** Vedolizumab staining (blue) on  $\alpha 4^+ \beta 7^+ \text{CD} 3^+ \text{CD} 4^+$  T cells compared to FMO control (red).

**C** Quantification of vedolizumab binding (n = 9) compared to unspecific staining in the FMO.

**D** Correlation of the frequency of  $\alpha 4^+ \beta 7^+$  with  $\beta 7^+ \text{VDZ}^+$  cells among CD3<sup>+</sup>CD4<sup>+</sup> T cells (n = 9). A regression line, Pearson's r and the associated p value are indicated.